Prostate cancer is a cancer that starts in the prostate, a small gland that sits below the bladder and in front of the rectum. It is the most common cancer in men aside from skin cancer, and the vast majority of cases are caught early enough to be cured. When detected before it spreads, the five-year survival rate is effectively 100%. Even so, understanding what prostate cancer is, how it develops, and what to expect from diagnosis and treatment can make a significant difference in how you navigate it.
What the Prostate Does
The prostate’s main job is producing fluid that becomes part of semen. This fluid contains enzymes, zinc, and citric acid that nourish sperm cells and lubricate the urethra (the tube that carries urine and semen out of the body). Muscles in the prostate also help push semen through the urethra during ejaculation. Because the prostate wraps around the urethra, any growth or swelling in the gland can directly affect urination, which is why urinary symptoms are often the first thing men notice.
How Prostate Cancer Develops
The prostate contains three cell types: luminal cells (which produce secretions), basal cells (which provide structural support), and rare neuroendocrine cells. Prostate cancer can originate from either luminal or basal cells, though the overwhelming majority of cases are adenocarcinomas, meaning they start in the gland-producing cells.
Development follows a recognizable path. It typically begins as a precancerous change called intraepithelial neoplasia, where luminal cells start multiplying abnormally and basal cells gradually disappear. If it progresses, it becomes a true adenocarcinoma that depends on male hormones (androgens) for growth. In later stages, some cancers evolve to no longer need androgens at all, which is called castration-resistant prostate cancer. This is generally when the disease becomes harder to control.
When prostate cancer spreads beyond the gland, different clones of cancer cells compete, and only those with the strongest survival advantages drive the disease forward. Metastases within a single patient tend to be closely related to each other genetically, even though the original tumor may have been quite diverse. The most common sites for spread are bones, lymph nodes, and less frequently the lungs or liver.
Common and Rare Types
About 95% of prostate cancers are acinar adenocarcinomas, the standard type that starts in the gland cells. This is what most people mean when they say “prostate cancer.” Ductal adenocarcinoma is a rarer subtype that starts in the tube-like ducts of the gland and tends to be more aggressive.
Several uncommon types exist. Small cell carcinoma is the most common neuroendocrine prostate cancer and behaves very differently from adenocarcinoma, growing quickly and often not producing PSA (the protein used in screening). Sometimes an adenocarcinoma transforms into a neuroendocrine cancer after hormone therapy, a shift known as treatment-related neuroendocrine carcinoma. Other rare forms include squamous cell carcinoma, sarcomas (which start in muscle or connective tissue), and lymphomas. These rare types together account for a small fraction of cases but require different treatment approaches.
Symptoms by Stage
Early prostate cancer often causes no symptoms at all. When it does produce signs, they tend to overlap with benign prostate enlargement, which is extremely common in older men. Early symptoms can include needing to urinate more often (especially at night), difficulty starting urination, blood in the urine or semen, and a weaker urine stream.
Advanced prostate cancer that has spread beyond the gland is more likely to cause bone pain (particularly in the back, hips, or pelvis), unexplained weight loss, urinary leaking, and unexplained fevers. Bone pain is especially characteristic of metastatic prostate cancer because the skeleton is the most common destination for spreading cancer cells. The challenge is that many men with early, curable prostate cancer have no symptoms, which is why screening plays such an important role.
Who Is Most at Risk
Age is the single strongest risk factor. Prostate cancer is rare before 40 and becomes increasingly common after 50, with most diagnoses occurring in men over 65.
Race plays a significant role. African American men are more likely to develop prostate cancer than any other group, more than twice as likely to die from it, and tend to be diagnosed at younger ages with more advanced disease. The reasons involve a combination of genetics, differences in access to care, and biological factors that aren’t fully understood.
Family history matters substantially. Your risk increases if you have a first-degree relative (father, brother, or son) who had prostate cancer, particularly if they were diagnosed before age 55. The risk climbs further if multiple family members across generations have been affected. Families with histories of breast, ovarian, or pancreatic cancer may carry inherited gene changes (like BRCA mutations) that also raise prostate cancer risk.
Screening and the PSA Test
The primary screening tool is a blood test that measures prostate-specific antigen, or PSA, a protein produced by both normal and cancerous prostate cells. There is no single PSA number that confirms or rules out cancer. Generally, a PSA above 4.0 ng/mL is considered elevated and may prompt further testing, but some doctors use a lower threshold of 2.5 ng/mL for younger men and a higher one (around 5 ng/mL) for older men, since PSA naturally rises with age.
An elevated PSA does not mean you have cancer. Infections, benign prostate enlargement, and even recent physical activity can raise PSA levels. If your PSA is elevated, your doctor will likely recommend an MRI of the prostate and possibly a biopsy, where small tissue samples are taken and examined under a microscope. The biopsy is what actually confirms or rules out cancer.
How Prostate Cancer Is Graded
If a biopsy confirms cancer, pathologists assign a Gleason score to describe how aggressive the cells look. The system works by identifying the two most prominent patterns in the tissue and assigning each a number from 1 to 5, then adding them together. A Gleason 3+3=6, for example, means both patterns look relatively normal and well-organized.
These scores are now grouped into five Grade Groups that are easier to interpret:
- Grade Group 1 (Gleason 6): Well-formed glands. A Gleason 6 cancer that is completely removed by surgery has a 96% cure rate at five years and essentially no potential for spreading.
- Grade Group 2 (Gleason 3+4=7): Mostly well-formed glands with a smaller poorly formed component. Roughly twice the risk of progression compared to Gleason 6.
- Grade Group 3 (Gleason 4+3=7): Mostly poorly formed glands. Despite having the same total score of 7, this carries about five times the risk of Gleason 6, a critical distinction.
- Grade Group 4 (Gleason 8): Poorly formed or fused glands throughout. About eight times the risk of Gleason 6.
- Grade Group 5 (Gleason 9-10): Little to no recognizable gland structure. The most aggressive, with nearly 12 times the risk of Gleason 6.
The difference between Gleason 3+4 and 4+3 is one of the most important distinctions in prostate cancer. They add up to the same number, but 4+3 carries substantially worse outcomes because the dominant pattern is the more aggressive one.
Survival Rates by Stage
Prostate cancer survival depends heavily on how far the cancer has spread at diagnosis. Based on data from the National Cancer Institute’s SEER program (2016-2022), five-year relative survival rates are:
- Localized (still within the prostate): 100%
- Regional (spread to nearby lymph nodes): 100%
- Distant (metastatic, spread to bones or distant organs): 40.1%
The vast majority of prostate cancers are caught at the localized or regional stage, where the outlook is excellent. Even for men diagnosed with metastatic disease, treatments have improved significantly, and many live for years with the disease under control.
Treatment Options
Treatment depends on the cancer’s grade, stage, your age, and your overall health. For low-risk prostate cancer, the preferred approach is now active surveillance rather than immediate treatment. This means monitoring the cancer with regular PSA tests, periodic MRI scans, and repeat biopsies every one to four years. The goal is to avoid the side effects of surgery or radiation for a cancer that may never cause harm, while catching any progression early enough to treat it curatively.
For men with limited life expectancy and no symptoms, watchful waiting is a less intensive alternative. It skips routine biopsies and only initiates treatment if the cancer starts causing problems.
When treatment is needed, the two main options for cancer that hasn’t spread are surgery (radical prostatectomy, which removes the entire prostate) and radiation therapy. During surgery, surgeons typically try to spare the nerves that run alongside the prostate, which control erections and bladder function. Radiation can be delivered externally in focused beams or through small radioactive seeds placed directly in the prostate. Both approaches have similar cure rates for most stages, and the choice often comes down to side effect profiles and personal preference.
For intermediate-risk cancers, the decision involves weighing all three approaches: active surveillance, surgery, or radiation (often combined with a period of hormone therapy). Higher-risk cancers with a Gleason score of 8 or above, or those that have spread to nearby lymph nodes, are typically treated with surgery or radiation combined with hormone therapy.
Hormone Therapy for Advanced Disease
Prostate cancer cells rely on androgens (primarily testosterone) to grow. Hormone therapy, called androgen deprivation therapy or ADT, works by cutting off this fuel supply. This can be done surgically by removing both testicles, which reduces testosterone by 90% to 95%, or more commonly through medications that block the brain’s signals telling the testicles to produce testosterone.
For metastatic prostate cancer, ADT alone was once the standard treatment, but current practice combines it with additional therapies. Men with metastatic disease now typically receive ADT plus a next-generation hormone blocker, sometimes with chemotherapy added, particularly for those with extensive spread. This combination approach has extended survival compared to ADT alone.
The limitation of hormone therapy is that most prostate cancers eventually adapt and learn to grow without androgens, becoming castration-resistant. At that point, treatment shifts to different drug combinations, though several effective options exist that can continue to control the disease for months or years.